Xact Kapitalforvaltning AB Invests $255,000 in Reata Pharmaceuticals Inc (NASDAQ:RETA)
Xact Kapitalforvaltning AB bought a new position in shares of Reata Pharmaceuticals Inc (NASDAQ:RETA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,700 shares of the company’s stock, valued at approximately $255,000.
Several other hedge funds have also made changes to their positions in RETA. Amundi Pioneer Asset Management Inc. bought a new position in Reata Pharmaceuticals in the first quarter valued at about $11,462,000. Rice Hall James & Associates LLC bought a new position in Reata Pharmaceuticals in the first quarter valued at about $9,908,000. Federated Investors Inc. PA bought a new position in Reata Pharmaceuticals in the first quarter valued at about $8,788,000. Bank of America Corp DE boosted its holdings in Reata Pharmaceuticals by 646.0% in the fourth quarter. Bank of America Corp DE now owns 74,432 shares of the company’s stock valued at $4,175,000 after acquiring an additional 64,454 shares during the last quarter. Finally, Deutsche Bank AG boosted its holdings in Reata Pharmaceuticals by 48.6% in the fourth quarter. Deutsche Bank AG now owns 171,372 shares of the company’s stock valued at $9,611,000 after acquiring an additional 56,039 shares during the last quarter. Institutional investors own 54.43% of the company’s stock.
Several equities analysts recently issued reports on the company. Citigroup set a $27.00 price target on StoneCo and gave the company a “hold” rating in a report on Friday, May 31st. BidaskClub upgraded Zebra Technologies from a “hold” rating to a “buy” rating in a report on Saturday, July 6th. ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, April 1st. Finally, Zacks Investment Research upgraded General Moly from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Reata Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $140.50.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Thursday, May 9th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.01). The business had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $7.92 million. Equities analysts expect that Reata Pharmaceuticals Inc will post -4.61 EPS for the current year.
In other news, insider Elaine Castellanos sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $85.20, for a total transaction of $170,400.00. Following the sale, the insider now owns 4,138 shares of the company’s stock, valued at $352,557.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Jason Douglas Wilson sold 4,000 shares of the firm’s stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $83.54, for a total value of $334,160.00. Following the sale, the chief financial officer now directly owns 4,000 shares in the company, valued at approximately $334,160. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,000 shares of company stock worth $1,202,760. Company insiders own 34.40% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.
Featured Article: Portfolio Manager
Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.